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Abstract
Background: The RTS,S/AS02D vaccine has been shown to have a promising safety profile, to be immunogenic and to
confer protection against malaria in children and infants.
Methods and Findings: We did a randomized, controlled, phase I/IIb trial of RTS,S/AS02D given at 10, 14 and 18 weeks of
age staggered with routine immunization vaccines in 214 Mozambican infants. The study was double-blind until the young
child completed 6 months of follow-up over which period vaccine efficacy against new Plasmodium falciparum infections
was estimated at 65.9% (95% CI 42.6–79.8, p,0.0001). We now report safety, immunogenicity and estimated efficacy
against clinical malaria up to 14 months after study start. Vaccine efficacy was assessed using Cox regression models. The
frequency of serious adverse events was 32.7% in the RTS,S/AS02D and 31.8% in the control group. The geometric mean
titers of anti-circumsporozoite antibodies declined from 199.9 to 7.3 EU/mL from one to 12 months post dose three of
RTS,S/AS02D, remaining 15-fold higher than in the control group. Vaccine efficacy against clinical malaria was 33% (95% CI:
24.3–56.9, p=0.076) over 14 months of follow-up. The hazard rate of disease per 2-fold increase in anti-CS titters was
reduced by 84% (95% CI 35.1–88.2, p=0.003).
Conclusion: The RTS,S/AS02D malaria vaccine administered to young infants has a good safety profile and remains
efficacious over 14 months. A strong association between anti-CS antibodies and risk of clinical malaria has been described
for the first time. The results also suggest a decrease of both anti-CS antibodies and vaccine efficacy over time.
Trial Registration: ClinicalTrials.gov NCT00197028
Citation: Aide P, Aponte JJ, Renom M, Nhampossa T, Sacarlal J, et al. (2010) Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria
Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial. PLoS ONE 5(11): e13838. doi:10.1371/journal.pone.0013838
Editor: Jennifer Keiser, Swiss Tropical Institute, Switzerland
Received June 12, 2010; Accepted October 15, 2010; Published November 4, 2010
Copyright:  2010 Aide et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: GlaxoSmithKline and Centro de Investigac ¸a ˜o em Sau ´de de Manhic ¸a both received financial support from the PATH Malaria Vaccine Initiative (MVI),
which was involved in all aspects of the study design and interpretation. MVI funded this work through a grant from the Bill & Melinda Gates Foundation. Core
funding for CISM is provided by the Spanish Agency for International Cooperation (AECI). The funders had no role in data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: MVI supports the development and testing of a number of malaria vaccines that can be seen as competitors. Amanda Leach, Marc
Lievens, Johan Vekemans, Marie-Claude Dubois, W. Ripley Ballou, and Joe Cohen are current or previous employees of GlaxoSmithKline Biologicals. Amanda
Leach, W. Ripley Ballou, Marie-Claude Dubois and Joe Cohen own shares in GlaxoSmithKline. Both Joe Cohen and W. Ripley Ballou are listed as the ‘Inventors’ of
patented malaria vaccines. However, neither individual holds a patent for a malaria vaccine. This does not alter the authors’ adherence to all the PLoS ONE policies
on sharing data and materials. None of the other authors in this paper have declared a conflict of interest.
* E-mail: pedro.aide@manhica.net
Introduction
Plasmodium falciparum malaria is one of the most serious public
health problems worldwide[1]. The need for improved prevention
tools cannot be overemphasized. A safe and effective malaria
vaccine to be used in malaria-endemic areas, particularly during
early stages of life, could greatly contribute to reducing the
enormous burden of malaria, and perhaps contribute to future
eradication efforts.
The last decade has witnessed important progresses in the
development of a first generation malaria vaccine. GlaxoSmithK-
line’s (GSK) RTS,S, formulated with the Adjuvant System AS02
or AS01, is currently the world’s most clinically-advanced malaria
vaccine candidate. This vaccine has been shown to be safe and
efficacious against malaria infection and disease in adult naı ¨ve and
semi-immune volunteers [2,3]. In 2004, we reported the first
proof-of-concept study in African children aged 1 to 4 years
showing that the vaccine was safe, immunogenic and reduced the
risk of P. falciparum infection, uncomplicated malaria and severe
disease, and that protection lasted for at least 45 months [4,5,6].
Recognizing that malaria control strategies must prioritize
protection in infants [7,8,9] led us to a I/IIb proof-of-concept trial
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in children less than 12 months of age. Vaccine efficacy (VE)
against malaria infection was 65.9% (95% CI 42.6–79.8,
p,0.0001) at the end of 6 months of follow-up [10].
A subsequent trial of the RTS,S/AS02D in Tanzanian infants
has recently shown very similar results [vaccine efficacy of 65.2%
(95% CI 20.7–84.7, p=0.01)] [11]. Furthermore, another trial in
children 5–17 months old with RTS,S/AS01E in Tanzania and
Kenya yielded a 53% (95% CI 28–69, p,0.001) reduction of
clinical malaria episodes over an 8 month follow up period [12].
This paper reports the safety, reactogenicity, immunogenicity
and efficacy of the complete 14 months follow-up period of the
Mozambican phase I/IIb proof-of-concept trial in infants, with
particular emphasis on safety and reactogenicity, given that it was
the first time that RTS,S formulated with AS02 was administered
to infants.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study site
The study was carried out by the Centro de Investigac ¸a ˜o em
Sau ´de de Manhic ¸a (CISM) in the rural areas of Taninga and Ilha
Josina Machel, 50 Km north of Manhic ¸a village, Mozambique,
from June 2005 to December 2007. Detailed description of the
area can be found elsewhere [10,13].
Study Design
This study was a phase I/IIb, randomized controlled trial to
assess the safety, immunogenicity and efficacy of the RTS,S/
AS02D vaccine administered to infants at 10, 14 and 18 weeks of
age, staggered with EPI vaccines (DTPw/Hib [TETRActHib
TM
Aventis Pasteur]) at 8, 12 and 16 weeks of age. The study was
double-blind until the youngest child completed 6 months of
follow-up. After the unblinding, the study was considered single
blinded although both participants and field investigators
remained blinded. Only a senior statistician had access to the
treatment codes allocated to the subjects, and he was not involved
in the children follow-up. Data provided to the field investigators
did not include information of the allocated treatment per subject
during the entire duration of the trial.
A total of 214 children were enrolled and randomized to receive
either RTS,S/AS02D or the control hepatitis B vaccine, Engerix-
B
TM. Details of the malaria and control vaccines as well as the trial
profile for the double-blind phase have been presented elsewhere
[10]. Briefly, all women who considered enrolling their infant in
the study were screened for hepatitis B surface antigen (HBsAg)
and human immunodeficiency virus (HIV) in their third trimester
of pregnancy. Written informed consent was obtained before any
blood was taken for testing.
Infants were screened between 6 and 12 weeks of age and a
second written informed consent was obtained from parents/
guardians of all participants. Infants were enrolled if they were
born after a normal gestational period and in the absence of
obvious medical abnormalities. Children born to Hepatitis B and
HIV positive mothers were not included in the trial. Children were
excluded as well from participation if BCG vaccine had not been
given at least one week before the first study vaccination or if any
other vaccinations, other than the first dose of oral polio vaccine
(OPV) given at birth with BCG, had been given prior to
enrolment. Identification cards were provided soon after recruit-
ment. Study activities were completed on December 27
th, 2007,
when the last recruited child completed 14 months of follow-up.
The protocol (NCT00197028) was approved by the Mozambi-
can National Bioethics Committee, the Hospital Clı ´nic of
Barcelona Ethics Review Committee and the PATH Human
Subjects Protection Committee and implemented according to the
International Conference of Harmonization and Good Clinical
Practices guidelines. GSK monitored the study. A Local Safety
Monitor and a Data and Safety Monitoring Board oversaw the
design, conduct and results of the trial.
The sample size for the original study was based on an
evaluation of vaccine safety [10]. A trial with 100 subjects in each
group had 80% power to detect a 2.6-fold increase in SAE rates if
the rate in controls was at least 10%. The trial also had 90%
power to detect an efficacy against malaria infection of 45% or
more assuming an attack rate of at least 75% in the control group
over the surveillance period. Efficacy against clinical malaria was
an exploratory endpoint.
Evaluation of safety
Safety endpoints included the occurrence of solicited and
unsolicited symptoms within 7 and 30 days after each vaccination
respectively and the occurrence of serious adverse events (SAEs)
during the entire 14 month follow-up period. All SAEs were
reported within 24 hours after detection.
Vaccine safety was evaluated using active and passive follow-up.
All study participants were observed for at least one hour after
each vaccine dose by a physician equipped with an emergency kit.
Children were visited daily in their homes for 6 days after
vaccination where any adverse events (AEs), local or general, were
registered on diary cards. Study physicians evaluated all suspected
grade 3 AEs and guided clinical management.
Passive follow-up was done through a health facility based
morbidity surveillance system [5,14]. All AEs irrespective of their
severity or relationship to vaccination were recorded during the 30
day period after each dose. SAEs were similarly detected and
reported throughout the study. Detailed definitions for solicited
and unsolicited AEs and SAEs as well as the classification of the
intensity can be found elsewhere [15].
Participants with SAEs were followed-up until events resolved.
Deaths occurring at home were investigated by a review of
available medical records and by verbal autopsy, as described
elsewhere [16].
Safety monitoring of hematological parameters [hemoglobin,
hematocrit, whole blood cell (WBC) and platelets] and biochem-
ical parameters [alanine amino transferase (ALT), total bilirubin
and creatinine] were measured one week after dose 1 and 1, 3K,
and 12 months after dose 3. Normality values considered were:
hemoglobin $80 g/L, hematocrit $25%, WBC 5-17610
9/L,
platelets $100610
9/L, ALT #60 mmol/L, creatinine #45 mmol/
L and bilirubin #34 mmol/L.
Biochemical, hematological and packed cell volume (PCV) tests
were determined as described elsewhere [10].
Evaluation of immunogenicity
Antibody titres were measured against hepatitis B surface
antigen (anti-HBs) and P. falciparum circumsporozoite protein (anti-
CS) at screening and 1, 3K and 12 months post dose 3.
Anti-CS antibodies were measured by a standardized ELISA,
using plates absorbed with recombinant R32LR with an assay cut-
off of 0.5 EU/mL. Anti-HBs antibodies were quantified using the
EIA kit from Abbott Laboratories and a GSK validated sandwich
ELISA described elsewhere [17]. The cut-off for the anti-HBs
ELISA was set at 10 mIU/mL.
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Cases of clinical malaria and malaria infection by P. falciparum
were ascertained by a combination of passive case detection (PCD)
and active detection of infection (ADI) as described elsewhere [10].
Briefly, two weeks prior to dose 3, all children received a
combination of amodiaquine and sulfadoxine-pyrimethamine to
clear any parasitemia. Two weeks after dose 3, children with
negative slides started ADI (performed bi-weekly for 12 weeks). At
each ADI visit, axillary temperature was recorded and parasitemia
determined. Children with positive results received antimalarial
treatment regardless of the presence or absence of symptoms and
were withdrawn from further ADI evaluation. PCD was
performed at Manhica District Hospital and Ilha Josina and
Taninga Health posts as described elsewhere [5,14].
The primary case definition of clinical malaria was the presence
of fever (axillary temperature $37.5uC) with a P. falciparum asexual
parasitemia .500/mL. This definition has a sensitivity and
specificity .90% in this age group [18]. The secondary case
definition was fever or history of fever in the previous 24 hours
plus any asexual P. falciparum parasitemia.
Exploratory efficacy endpoints were first or only clinical episode
of P. falciparum malaria as well as multiple episodes of clinical
malaria detected by PCD during 14 months after dose 1. An
additional endpoint was first or only clinical episode of P. falciparum
malaria detected by a combination of ADI and PCD.
Statistical methods
Analyses were done for intention to treat (ITT) and according to
protocol (ATP) cohorts, following a predefined analytical plan.
The ITT cohort included all children who received at least one
dose of the study vaccine. All safety analyses were based on ITT.
The ATP cohort included participants that met all eligibility
criteria, completed the vaccination course and contributed to
follow-up time during the evaluation period. For exploratory
analyses, the ATP cohort was split into two follow-up periods:
follow-up over study months 3–9 (ATP3–9) and study months 3–14
(ATP3–14). VE explored both first or only episode and multiple
episodes of clinical malaria detected during the two study periods.
Analysis of immunogenicity was based on the ATP cohort,
excluding children that received any blood product, immunosup-
pressant or immune-modifying therapy. Measurements of anti-CS
and anti-HBs antibodies were summarized by Geometric Mean
Titres (GMTs) with 95% confidence intervals (95% CI). Titres
below the cut-off were assigned an arbitrary value of half the cut-
off of the assay for the purpose of GMT calculation.
Person years at risk (PYAR) accounted for absences from the
study area and use of antimalarial drugs as previously described
[5].
VE was defined as 1 minus the hazard ratio multiplied by 100
[(1 – HR)*100] and was adjusted for distance to health facility [5]
and community of residence. The adjusted VE was assessed using
Cox regression models (for the first or only episode) and Poisson
regression (for multiple episodes).
A test based on the Schoenfeld residuals was performed to assess
whether the hazard was constant over the surveillance period, and
alternative approaches were applied if the assumption of
proportional hazards was not supported.
The risk of clinical malaria as a function of immune response
was evaluated by comparing post-vaccination anti-CS titters for
RTS,S/AS02D recipients who either did or did not experience at
least one episode of clinical malaria meeting the primary case
definition over ATP3–14 follow-up, using the Wilcoxon Rank Sum
test. The hazard rate per 2-fold increase in post-vaccination anti-
CS response was calculated for both ATP3–9 and ATP3–14 follow-
up, along with their 95% confidence intervals.
Analyses were performed using SAS version 9.1 (Cary, NC,
USA) and STATA version 10 (College Station, TX, USA).
Results
Of the 251 infants aged 6 to 12 weeks screened for eligibility,
214 were recruited and randomized to the RTS,S/AS02D group
(107) or the control group (107). A total of 177 children completed
the 14 months follow-up period: 91 in the RTS,S/AS02D group
and 86 in the Engerix-B
TM group (Fig. 1). Results of the initial 3.5
months of follow-up were reported elsewhere [10].
Vaccine safety
Safety data was available for 214 children. 107 received 301
doses of RTS,S/AS02D and 309 doses of TETRActHib
TM and 107
received 303 doses of Engerix-B
TM and 311 doses of TETRA-
ctHib
TM. Compliance for completion of symptoms questionnaires
was 100%.
Solicited AEs after RTS,S/AS02D or Engerix-B
TM
vaccinations. Three recipients of the Engerix-B
TM vaccine
reported grade 3 solicited general symptoms, all of them
considered to be related to the vaccine but resolving within the
7 day follow-up period (Table 1). None of the RTS,S/AS02D
group participants reported grade 3 solicited general events. None
of the solicited local symptoms reported in either group were of
grade 3 intensity.
In both groups the most common solicited local symptom was
pain at the injection site. There was no apparent trend in
incidence of either pain or swelling with subsequent doses of
RTS,S/AS02D or Engerix-B
TM.
Solicited AEs after TETRActHib
TM vaccinations. Five
children (4 in the Engerix-B
TM and 1 in the RTS,S group)
experienced grade 3 solicited general symptoms following either
the first or the second TETRActHib
TM dose (Table 2). All of these
events were considered to be related to vaccination and the
children fully recovered. None of the solicited local symptoms were
reported to be of grade 3 intensity.
Pain at the injection site was the most frequently reported
solicited local symptom. The incidence of pain and swelling was
similar in both vaccine groups. There was no apparent trend in
incidence of either pain or swelling with subsequent doses of
TETRActHib
TM.
Unsolicited adverse events. Unsolicited AEs occurring
within 30 days following vaccination were reported by 86.9% of
participants in both vaccine groups. In both groups, the most
frequently reported diagnosis was upper respiratory tract infection
(49.5% of subjects in the RTS,S/AS02D and 45.8% of subjects in
the Engerix-B
TM group) (data not shown).
No unsolicited AE was considered to be causally related to the
study vaccines.
Grade 3 unsolicited events were rare, occurring with similar
frequency in both comparison groups. Five subjects (4.7%)
reported ten grade 3 unsolicited AEs in the RTS,S/AS02D group
[anemia (4), bronchopneumonia (1), P. falciparum infection (4),
pneumonia (1)] and seven subjects (6.5%) reported twelve grade 3
unsolicited AEs in the Engerix-B
TM group [anaemia (1), conjunc-
tivitis (1), pyrexia (1), bronchitis (1), bronchopneumonia (1), skin
furuncle (1), gastroenteritis (3), pneumonia (2), bronchospasm (1)]
(data not shown).
SAEs. There were 69 children with at least one SAE (35 in the
RTS,S/AS02D and 34 in the Engerix-B
TM group) as shown in
Table 3. The proportion of subjects reporting an SAE was similar
RTS,S/AS02D Extended Follow-Up
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group (31.8%, 95% CI 23.1–41.5). None of them were considered
to be related to vaccination. The total number of SAEs classified
according to the Medical Dictionary for Regulatory Activities
(MedDRA)[19] preferred terms was 157 (75 in the RTS,S/AS02D
and 82 in the control group).
During the entire follow-up period, 15 participants in the
RTS,S/AS02D group reported P. falciparum as an SAE requiring
hospitalization, corresponding to 14.0% (95% CI 8.1–22.1). In the
control group, there were 13 participants hospitalized with
malaria, corresponding to 12.1% (95% CI 6.6–19.9). All cases
fully recovered. The other main diagnoses of SAEs requiring
admission were anaemia (15.9% vs 12.1%) gastroenteritis (12.1%
vs 16.1%) and pneumonia (8.4% vs 7.5%) in the RTS,S/AS02D
and Engerix-B
TM groups, respectively (data not shown).
Four deaths occurred during follow-up (two in each group).
None of the deaths was judged to be related to vaccination. In the
RTS,S/AS02D group, an eight month old girl died at home four
months after having received a study vaccine. The presumptive
diagnosis based on the verbal autopsy obtained from the mother
was staphylococcal septic shock (recorded history of fever,
generalised vesicular eruption, skin peeling and face swelling prior
to death).
The second death in this group also occurred at home nine
months after the child had received the last study vaccination.
The 15 month HIV negative old boy had previously been
admitted for a Streptococcus pneumoniae pneumonia (confirmed by a
positive blood culture) and anaemia. According to the verbal
autopsy, the death occurred after about 3 weeks of fever,
vomiting, diarrhoea, abdominal pain and pallor. The parents did
not seek treatment at any health facility. The final diagnosis
following verbal autopsy review was chronic gastroenteritis with
severe dehydration.
In the Engerix-B
TM group, a 10 month old boy died at home six
months after receiving the third dose of the vaccine. The child had
been seen by a field worker 3 days before he died and he appeared
to be in good health. The verbal autopsy performed to the mother
revealed that 24 hours prior to the fatal event the child abruptly
started with intense vomiting and diarrhoea. The mother took him
to a traditional healer who administered him ‘‘traditional
medication’’. The child died shortly after. The probable cause of
death was severe dehydration from gastroenteritis. The possibility
of an adverse effect secondary to traditional medicine ingestion
could not be excluded.
The second death was of an 11 month old girl, who died at
home 7 months after the last vaccination with Engerix-B
TM.
Figure 1. Trial Profile.
doi:10.1371/journal.pone.0013838.g001
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for 4 days, stopped eating, and progressively developed sunken
eyes and pallor. The child was not brought to the health centre.
Clinician’s review of the verbal autopsy report concluded that the
most probable cause of death was severe dehydration secondary to
gastroenteritis.
Monitoring of hematological and biochemical
parameters. Hematological values outside the normal range
were infrequent. The majority of abnormal values of hemoglobin,
white blood cells and platelets were of grade 1 intensity and
occurred with similar incidence in the two groups. One child with
concomitant malaria in the RTS,S/AS02D group had a low
platelet count (44610
9/L) of grade 2 intensity one month after the
last vaccination. This value was within the normal range
(167610
9/L) at month 6.
Biochemistry values outside the normal range were also
infrequent. The majority of out of range ALT and bilirubin
values were of grade 1 intensity, occurring with a similar incidence
in the two groups. One participant in the RTS,S/AS02D group
had a grade 2 ALT value one week after the first dose (162 mmol/
L) which dropped to 38 mmol/L one month after the third dose
and to 39 mmol/L by study month 6. No creatinine values were
outside the normal ranges.
Vaccine immunogenicity
ATP analysis of vaccine immunogenicity at month 14 included
151 children (73 in the RTS,S/AS02D and 78 in the control
group). The anti-CS antibody GMTs declined from 199.9 EU/
mL one month post dose 3 to 58.8 EU/mL and 7.3 EU/mL by
3.5 and 12 months post dose 3 respectively in the RTS,S/AS02D
group. In the control group, anti-CS antibody GMTs were below
the assay cut off (0.5 EU/mL) at all post vaccination time points.
In the RTS,S/AS02D group, the anti-HBs antibody GMTs
declined from 10082 mIU/mL one month after dose 3 to
2751 mIU/mL by 12 months post dose 3. In the Engerix-B
TM
group, the anti-HBs GMTs were 392.4 mIU/mL and
263.9 mIU/mL at the same time points. All children of both
RTS,S/AS02D and control groups were seroprotected for
Hepatitis B at 12 months post dose 3.
Vaccine efficacy
Results of VE analyzed over three different time periods are
summarized in Table 4.
It should be noted that the trial was not powered for VE against
clinical malaria and all analyses herein are exploratory.
VE analysis between months 3 to 9 of follow-up (ATP3–9) was
48.8% (95% CI 11.3–70.4, p=0.017) against first or only clinical
Table 1. Incidence of solicited general symptoms by dose within the 7-day follow-up after RTS,S/AS02D or Engerix-B
TM.
After dose 1 After dose 2 After dose 3
RTS,S/AS02D Engerix -B RTS,S/AS02D Engerix -B RTS,S/AS02D Engerix-B
(N=105) (N=106) (N=99) (N=100) (N=97) (N=97)
n% n% N% n % n% n%
General symptoms
Drowsiness
Any 27 25.7 37 34.9 32 32.3 26 26.0 28 28.9 32 33.0
Related 10 9.5 11 10.4 8 8.1 3 3.0 3 3.1 5 5.2
Fever
Any 11 10.5 5 4.7 10 10.1 10 10.0 8 8.2 9 9.3
Related 11 10.5 5 4.7 10 10.1 9 9.0 8 8.2 9 9.3
Grade 3 0 - 0 - 0 - 1 1.0 0 - 1 1.0
Grade 3 related 0 - 0 - 0 - 1 1.0 0 - 1 1.0
Irritability
Any 43 41.0 39 36.8 49 49.5 39 39.0 42 42.3 46 47.4
Related 27 25.7 13 12.3 25 25.3 16 16.0 17 17.5 20 20.6
G r a d e 3 0- 0- 0- 0 - 0- 11 . 0
Grade 3 related 0 - 0 - 0 - 0 - 0 - 1 1.0
Loss of appetite
Any 19 18.1 27 25.5 25 25.3 24 24.0 28 28.9 29 29.9
Related 2 1.9 1 0.9 1 1.0 1 1.0 3 3.1 3 3.1
Local symptoms
Pain
Any 103 98.1 95 89.6 92 92.9 82 82.0 80 82.5 81 83.5
G r a d e 3 0- 0- 0- 0 - 0- 0-
Swelling
Any 10 9.5 12 11.3 11 11.1 8 8.0 8 8.2 8 8.2
G r a d e 3 0- 0- 0- 0 - 0- 0-
N= Number of subjects with at least one symptom sheet completed; n/%= number and percentage of subjects reporting a specified symptom.
doi:10.1371/journal.pone.0013838.t001
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multiple episodes.
VE against first or only episodes of clinical malaria over the
entire follow-up period up to month 14 (ATP3–14) was 33.0% (95%
CI -4.3–56.9, p=0.076) and VE against multiple malaria episodes
was 25.9% (95% CI -15.7–52.6, p=0.167). Figure 2 shows
Kaplan-Meier curves of the cumulative incidence of first or only
episodes of clinical malaria in both groups. A test based on the
Table 2. Incidence of solicited general symptoms by dose within the 7-days follow-up after TETRActHib
TM according to
randomization group.
After dose 1 After dose 2 After dose 3
RTS,S/AS02D Engerix -B RTS,S/AS02D Engerix -B RTS,S/AS02D Engerix -B
(N=107) (N=107) (N=102) (N=104) (N=100) (N=100)
n% n % N% n % n% n%
General symptoms
Drowsiness
Any 31 29.0 25 23.4 29 28.4 27 26.0 28 28.0 30 30.0
Related 12 11.2 12 11.2 3 2.9 8 7.7 5 5.0 3 3.0
Grade 3 0 - 1 0.9 0 - 0 - 0 - 0 -
Grade 3 related 0 - 1 0.9 0 - 0 - 0 - 0 -
Fever
Any 10 9.3 13 12.1 6 5.9 12 11.5 8 8.0 5 30.0
Related 10 9.3 13 12.1 6 5.9 12 11.5 8 8.0 5 3.0
Grade 3 0 - 1 0.9 1 1.0 1 1.0 0 - 0 -
Grade 3 related 0 - 1 0.9 1 1.0 1 1.0 0 - 0 -
Irritability
Any 59 55.1 59 55.1 44 43.1 48 46.2 49 49.0 50 50.0
Related 40 37.4 47 43.9 18 17.6 29 27.9 26 26.0 23 23.0
Grade 3 0 - 1 0.9 0 - 0 - 0 - 0 -
Grade 3 related 0 - 1 0.9 0 - 0 - 0 - 0 -
Loss of appetite
Any 22 20.6 15 14.0 26 25.5 20 19.2 27 27.0 30 30.0
Related 3 2.8 2 1.9 0 - 1 1.0 4 4.0 3 3.0
Local symptoms
Pain
Any 105 98.1 103 96.3 98 96.1 102 98.1 92 92.0 93 93.0
G r a d e 3 0- 0 - 0- 0 - 0- 0-
Swelling
Any 22 20.6 18 16.8 14 13.7 22 21.2 16 16.0 22 22.0
G r a d e 3 0- 0 - 0- 0 - 0- 0-
N= Number of subjects with at least one symptom sheet completed; n/%= number and percentage of subjects reporting a specified symptom.
doi:10.1371/journal.pone.0013838.t002
Table 3. Percentage of participants reporting SAEs classified by MedDRA primary organ class and preferred term over 14 months
follow-up.
Engerix-B (N=107) RTS,S/AS02D (N=107)
n % 95% CI n % 95% CI
Number of subjects with at least one SAE reported 34 31.8 23.1–41.5 35 32.7 24.0–42.5
Number of SAEs reported classified by MedDRA preferred term* 82 76.6 67.5–84.3 75 70.1 60.5–78.6
N = number of subjects with at least one administered dose and included in ITT cohort.
n/% = number/percentage of subject reporting at least once the symptom.
*Symptoms reported by a subject after a given dose and classified by the same Preferred Term are counted once.
doi:10.1371/journal.pone.0013838.t003
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proportional over the follow-up period, consistent with the notion
that VE waned over the course of the study.
Analysis of the relationship between anti-CS antibody levels and
VE against clinical malaria suggested that within RTS,S
recipients, the hazard rates of disease per 2 fold increase anti-CS
titres at one month post dose 3 were significantly reduced by
84.1% (95% CI 43.5–95.5, p=0.004) and 72.4% (95% CI 35.1–
88.2, p=0.003)forthetwofollow-upperiods(ATP3–9andATP3–14),
respectively.
Discussion
This is the first comprehensive safety and reactogenicity report
of RTS,S/AS malaria vaccine in infants. We previously reported
that VE against new P. falciparum infections was 65.9% during the
Table 4. Vaccine efficacy evaluated for different follow-up periods.
Engerix B (n=92)
RTS,S/AS02D
(n=93) Vaccine Efficacy
Events PYAR Rate Events PYAR Rate 95% CI p
ATP(3–9)
First or only (FO) episode of fever and parasitemia .500/ml 34 31.5 1.08 21 38.2 0.55 48.8% 11.3–70.4 0.017
FO episode of fever or history of fever* and parasitemia .0/ml 48 27.7 1.74 29 36.4 0.80 54.5% 27.3–71.5 0.001
Multiple episodes of fever and parasitemia.500/ml 45 36.2 1.24 23 40.2 0.57 53.7% 21.4–72.7 0.004
Multiple episodes of fever or history of fever* and parasitemia .0/ml 72 36.0 2.00 34 40.0 0.85 58.9% 35.8–73.6 ,0.001
ATP(3–14)
First or only (FO) episode of fever and parasitemia .500/ml 45 51.3 0.88 36 61.7 0.58 33.0% 24.3–56.9 0.076
FO episode of fever or history of fever* and parasitemia .0/ml 57 41.4 1.38 45 57.1 0.79 41.9% 13.7–60.9 0.007
Multiple episodes of fever and parasitemia.500/ml 74 68.9 1.07 58 72.5 0.80 25.9% 215.7–52.6 0.187
Multiple episodes of fever or history of fever* and parasitemia .0/ml 120 68.4 1.75 85 72.3 1.18 35.1% 2.2–57.0 0.039
ITT**(0–14)
First or only (FO) episode of fever and parasitemia .500/ml 54 79.4 0.68 46 90.2 0.51 25.9% 29.9–50.0 0.136
Multiple episodes of fever and parasitemia.500/ml 105 111 0.94 82 113 0.72 24.3% 212.9–49.2 0.173
Multiple episodes of fever and parasitemia.500/ml (PCD only) 95 112 0.85 80 113 0.71 17.6% 224.2–45.3 0.355
*History of fever in previous 24 hours.
**ITT: n=107 for each group.
PYAR= Persons-years at risk. Vaccine efficacy adjusted estimates for area and distance from health center (km).
ATP= According to the Protocol; ITT= Intention to Treat; PCD= Passive Case Detection.
doi:10.1371/journal.pone.0013838.t004
Figure 2. Kaplan-Meier curves for the cumulative proportion of children with at least one episode of clinical malaria between study
months 3 to14 (ATP 3–14).
doi:10.1371/journal.pone.0013838.g002
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staggered schedule with routine EPI vaccines [10]. This report
goes further to include an exploratory analysis of VE against
clinical malaria observed during the study.
The RTS,S/AS02D reactogenicity profile was similar to that
recorded in previous trials in older age groups [2,5]. The safety
profile in infants remained promising during the extended follow-
up, with no significant differences between groups in the frequency
of SAEs. No safety signals were found in the monitoring of
hematologic and biochemistry data.
We observed no strong evidence of significant differences in the
immunological responses to vaccination with RTS,S/AS02D in
infants in this trial compared to older children. Anti-CS antibody
titters decayed over time. However, there is no evidence that they
did so more precipitously in this trial compared to other pediatric
trials, where antibody decay profiles are consistent with a half-life
of 6 to 8 weeks. In this trial, anti-CS responses at 12 months post-
dose 3 remain 15 fold higher in the RTS,S/AS02D group than in
the control group. Where longer follow-up data are available, low
but persistently elevated anti-CS responses have been reported
(10–30 times higher than in controls) also [6]. This is consistent
with the induction of long term T cell and B cell memory
responses by RTS,S/AS02. Such persistence of antibody responses
is likely to be seen in this infant population but this can only be
confirmed by longer follow-up as planned in the ongoing Phase 3
trials.
Anti-HBs responses were higher throughout the follow-up in
recipients of RTS,S/AS02D than of the licensed Hepatitis B
control vaccine probably reflecting the use of a different adjuvant
system. HBs antibody titters also decayed over time. However, all
children vaccinated with both RTS,S/AS02D and Engerix-B
TM
vaccines reached seroprotection levels for anti-HBs 12 months post
Dose 3.
Vaccine efficacy against clinical malaria over the 12 months
follow-up period after dose three was 33% (95% CI -4.3–56.9,
p=0.076), whereas during the initial 3.5 months of double-blind
follow-up the efficacy was 65.8% (95% CI 25.3–84.4, p=0.007).
This difference could be due to chance as the confidence intervals
of the two estimates overlap, and the study is underpowered for
such analyses. Nevertheless, together with the data showing that
the hazard was not proportional over the follow-up periods, the
results suggest that VE against clinical malaria may have waned
over the 14 months follow-up period.
Caution is needed when attempting to compare the results of
this study with data reported from a previous phase IIb trial
conducted in this same area among children aged 1 to 4 years [5].
Cohort 2 of that trial had a very similar design to the infant study
that we are reporting, including the administration of presumptive
treatment with effective antimalarials between dose 2 and 3 and an
initial follow-up through intense active detection of infections
(ADI). In both studies, VE against clinical malaria appeared to
wane over time [20]. This is in sharp contrast to cohort 1 of the
phase IIb trial where children were only followed-up by passive
case detection and did not have presumptive treatment. Among
these children VE persisted at 30% for 45 months [6]. Reasons for
this apparent differences in the duration of protection are
discussed elsewhere [20].
While several previous trials have shown a relationship between
anti-CS antibody responses and risk of malaria infection, this study
provides the first evidence of a similar relationship between anti-
CS antibodies and protection against clinical malaria. It is
probable that in trials in older populations similar analyses have
been confounded by the superimposed naturally acquired
immunity.
In summary, these results confirm the good safety and
immunogenicity profile of RTS,S/AS02D malaria vaccine in
African infants, as well as confirm protection against clinical
malaria for at least one year. Together they support the rationale
for the ongoing Phase III trial.
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